[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571317":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":62,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":25,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Hunter Holmes Mcguire Veteran Affairs Medical Center","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Patients will be given placebo and actual drug sequentially with the order hidden",[13],"Drug: Placebo",{"label":15,"type":16,"description":11,"interventionNames":17},"Rifaximin SSD 40mg IR BID","EXPERIMENTAL",[18],"Drug: Rifaximin SSD 40 mg IR tablet",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Rifaximin SSD 40 mg IR tablet","Drug therapy vs placebo",[15],null,{"type":21,"name":9,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo drug",[9],[30],{"name":31,"affiliation":32,"role":33},"Jasmohan Bajaj","Richmond VA Medical Center","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Jasmohan S Bajaj, MD","CONTACT","804-675-5802","jasmohan.bajaj@vcuhealth.org",{"name":41,"role":37,"phone":42,"phoneExt":25,"email":43},"Haley Obolewicz, RN","804-675-5705","haley.obolewicz@va.gov",[45],{"facility":32,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Richmond","Virginia","23249","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-77.46026,37.55376,{"lat":56,"lon":55},[59],{"name":41,"role":37,"phone":60,"phoneExt":61,"email":43},"804-675-5000","15705",{"type":63,"investigatorFullName":31,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Staff Physician",[66],{"name":67,"class":68},"Bausch Health Americas, Inc.","INDUSTRY","100571317","phase-1-rifaximin-ssd-in-dementia-trial-100571317",false,"NCT06718686","Rifaximin SSD in Dementia Trial","Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia","RIDE","Inclusion Criteria:\n\n* Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale.\n* Males and Females Age ≥ 65 years\n* Community living with availability of caregiver to accompany participant to study visits and to participate in the study.\n* Able to consent or legal guardian who can consent (with participant assent).\n* Legally authorized representative (LAR) and caregiver for the study is the same individual.\n* Fluency (both participant and caregiver) in written and spoken English to participate in study visits.\n\nExclusion Criteria:\n\n* Dementia not due to AD or VaD\n* Clinically significant agitation or aggression (requiring treatment with antipsychotic medication)\n* Delusions and\u002For hallucinations\n* Severe psychopathology including major depression\n* Unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history\n* Visual and\u002For hearing disorder that prevents completion of neuropsychologic evaluations.\n* Diarrhea\n* Hypersensitivity to rifaximin, components of rifaximin,\n* and any rifamycin antimicrobial agent\n* Antibiotic use in the prior 6 months\n* Taking medications that interact with Rifaximin. P-glycoprotein (P-gp) inhibitor treatment is permitted as long as the use of P-gp inhibitors is discussed with the investigator.\n* History of alcohol and\u002For drug abuse\n* Participation in another investigational drug trial in the last 30 days","ALL","65 Years",{"count":80,"type":81},20,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE1","PHASE2","Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.",[88,89],"Dementia Alzheimer Type","Dementia Associated With Cerebrovascular Disease",[91,92,93,94,95],"dementia","rifaximin","gut-brain","Alzheimer's","vascular dementia","2026-04-01",{"date":98,"type":99},"2026-04-03","ACTUAL",{"date":101,"type":99},"2024-12-30",{"date":103,"type":81},"2027-12-30",{"name":31,"class":6},1]